K Naga Swetha’s scientific contributions

The present research work is aimed to design oral twice a daily sustained release matrix tablets of Mebeverine hydrochloride 135mg, used for treating or preventing spasmodic conditions of the lower gastrointestinal tract which can release the drug for 10 to 12 hours. The tablets were prepared by the Wet granulation method using varying concentrations of sustained release polymers HPMC, Eudragit and Ethyl cellulose. The compatibility of the polymers was ruled out by FT-IR studies and found to be compatible. Total nine formulations were prepared. The Mebeverine hydrochloride powder and the powder-blends of tablets were evaluated for their physical properties like angle of repose, bulk density and compressibility index and found to have good flow property. The prepared tablets were evaluated for in process and finished product quality control tests including appearance, dimensions, weight variation, hardness, friability, drug content, and in vitro drug release. The dissolution medium used was pH 6.8 phosphate buffer. All formulations showed acceptable pharmaco-technical properties and complied with in-house specifications for tested parameters. The results of dissolution studies indicated all formulations released up to 12hours and formulation containing Ethyl cellulose (5%) i.e. F 7 was the most successful formulation with 96.72% drug release at the end of 12 hours.